Publications by authors named "E Colby"
Diagnosis of Lyme borreliosis (LB) is prone to under ascertainment with the true extent of infection unknown. Cross sectional age-stratified population-based serological survey data may provide insight into this issue. Using data from a previously published Dutch seroprevalence study, we describe the application of catalytic models to make estimates of the annual extent of LB infection.
View Article and Find Full Text PDFArticle Synopsis
- Lyme borreliosis (LB) is the most prevalent tick-borne disease in Europe, particularly in southern coastal Norway, where it often presents as erythema migrans and can lead to severe complications like Lyme neuroborreliosis or arthritis.
- From 2012 to 2022, the incidence of reported laboratory-confirmed disseminated LB cases in Norway increased by 78%, highlighting the growing concern over this disease.
- A study estimated that the symptomatic LB cases in adults ranged from 315-630 per 100,000 in five southern coastal counties in 2022, indicating a significant underreporting in public health surveillance where only 24-48 symptomatic cases were documented for each reported case.
Objectives: To better understand the Lyme borreliosis (LB) burden in Europe, we aimed to estimate the incidence of symptomatic Borrelia burgdorferi sensu lato (Bbsl) infections after adjusting public health LB surveillance data for under-detection of symptomatic Bbsl infections.
Methods: Data from seroprevalence studies and estimates of the symptomatic proportion and duration of antibody detection in Bbsl-infected individuals, derived from reviews of the published literature, were used to adjust public health LB surveillance data to estimate the incidence of symptomatic Bbsl infection in nine European countries from 2018 to 2022.
Results: The prevalence of anti-Bbsl antibodies ranged from 2.